2022
DOI: 10.3390/healthcare10122579
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Different Dosing Regimens of IgE Targeted Biologic Omalizumab for Chronic Spontaneous Urticaria in Adult and Pediatric Populations: A Meta-Analysis

Abstract: Chronic urticaria is a debilitating skin condition that is defined as itchy hives at least twice a week and lasting for six or more weeks, with or without angioedema. Chronic spontaneous urticaria (CSU) is a form of disease that is witnessed in two-thirds of those with chronic urticaria. This meta-analysis explores the efficacy of differential dosages of omalizumab for outcomes of weekly itching scores, weekly wheal scores, urticarial assessment score 7 (UAS7), and responder rates. Adhering to PRISMA Statement… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
6
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 55 publications
(94 reference statements)
1
6
1
Order By: Relevance
“…In 2021, Surapon conducted a network meta-analysis to evaluate the effect of biologic drug therapy on H1-antihistaminerefractory CSU, which proved that omalizumab (300 or 600 mg) could be recommended as an effective treatment for CSU patients 33 . Previous metaanalysis results are consistent with the conclusions of our cumulative meta-analysis, which will help inform clinical treatment expectations and policy decisions [34][35][36] .…”
Section: Comparison With Other Studiessupporting
confidence: 84%
“…In 2021, Surapon conducted a network meta-analysis to evaluate the effect of biologic drug therapy on H1-antihistaminerefractory CSU, which proved that omalizumab (300 or 600 mg) could be recommended as an effective treatment for CSU patients 33 . Previous metaanalysis results are consistent with the conclusions of our cumulative meta-analysis, which will help inform clinical treatment expectations and policy decisions [34][35][36] .…”
Section: Comparison With Other Studiessupporting
confidence: 84%
“…To the best of our knowledge, this is the first NMA studying the efficacy and safety of varying dosage levels of omalizumab in a population of all ages with CIU. Unlike other meta‐analysis studies, this NMA analyzed the latest data from 12 eligible RCTs “head to head” 16,41 . The aggregate data network meta‐analysis ensured that we thoroughly examined these interventions in greater detail, enabling us to determine the magnitude of the efficacy among interventions and identify factors contributing to adverse events.…”
Section: Discussionmentioning
confidence: 99%
“…The 300 mg dose can be regarded as the plateau dose, but it remains uncertain whether doses between 300 and 600 mg offer any further benefits 74–76 . On the other hand, a recent meta‐analysis suggests that considering dose‐response relationships is relevant as there is slightly better performance observed with 300 mg doses compared to 150 mg doses 16 . However, our results contradict this finding in which a 300 mg dose of omalizumab is evidently more effective than a 150 mg dosage.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations